Skip to main content
OpenTrials
Completed

NCT Number: NCT03398889

Intestinal Microbiome and Extremes of Atherosclerosis

Patients attending stroke prevention clinics and a premature atherosclerosis clinic at University Hospital in London, ON, Canada were recruited to the study. They completed a dietary questionnaire, provided stool samples and had blood drawn to measure plasma levels of metabolites produced by the intestinal bacteria.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Stroke Prevention & Atherosclerosis Research Centre

London, Ontario, N6G 2V4, Canada

About this study

Patients were phenotyped by their residual score in linear multiple regression with measured carotid plaque burden as the dependent variable and coronary risk factors were predictors. The residual score essentially represents the distance off the regression line of predicted plaque. They were grouped into three categories: Unexplained atherosclerosis (with more plaque than predicted by risk factors; residual score >2); Explained (the amount of plaque predicted by risk factors, residual score >-2 and <2); and Protected (less plaque than predicted by risk factors, residual score <-2).

DNA was extracted from stool samples in the lab of Dr. Allen-Vercoe at University of Guelph. RNA makeup of the intestinal microbiome was assessed in the lab of Dr. Gregory Gloor at Western. Plasma levels of trimethylamine n-oxide, p-cresylsulfate, hippuric acid, p-cresyl glucuronide, pheny acetyl glutamine and phenyl sulfate were measured by ultra-performance liquid chromatography coupled to quadrupole time-of-flight mass spectrometry in the lab of Dr. Bradley Urquhart at Western.

Nutrient intake over the past year was calculated at the Harvard School of Public Health from the 131 item self-reported and semi-quantitative Harvard Food Frequency Questionnaire (FFQ).

Estimated glomerular filtration rate was calculated from the Chronic Kidney Disease Epidemiological (CKD-EPI) equations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients attending stroke prevention clinics and a Premature Atherosclerosis Clinic at University Hospital, London, ON, Canada,
  • with measurements of carotid plaque burden and the risk factors used in the linear regression model.
  • Willing to consent to the protocol approved by the Ethics board

Exclusion criteria

  • Missing data on variables used in the regression model,

Treatment and study plan

Plasma levels of metabolites

Diagnostic Test

plasma levels of metabolites

Dietary questionnaire

Behavioral

Harvard food frequency questionnaire

Intestinal microbiome

Diagnostic Test

amplification and sequencing of 16S rRNA gene variable regions in stool samples

Primary outcomes

  1. Plasma levels of metabolites in the three phenotypes

    Time frame: Day 1

    Plasma levels of trimethylamine n-oxide, p-cresylsulfate, hippuric acid, p-cresyl glucuronide, pheny acetyl glutamine and phenyl sulfate

Secondary outcomes

  1. Bacterial profile of the intestinal microbiome

    Time frame: Day 1

    Amplification and sequencing of 16S rRNA gene variable regions

  2. Effect of nutrient intake on plasma levels of metabolites

    Time frame: Day 1

    Nutrient analysis from food frequency questionnaire

  3. Effect of renal function on plasma levels of metabolites

    Time frame: Day 1

    eGFR from CKD-EPI equations

Sponsors and collaborators

Lead sponsor

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Other

Registry information

Important dates

Study start
2014
Primary completion
2016
Study completion
2016
First posted
Jan 16, 2018
Registry last updated
Jan 16, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.